Boehringer Ingelheim Archives -

Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop

Boehringer takes option on masked cytokine specialist Trutino

https://pharmaphorum.com/news/boehringer-takes-option-on-masked-cytokine-specialist-trutino/

Boehringer Ingelheim, Biberach, Germany, February 2007

Digital/ News/ News

Boehringer sells drug safety software to ArisGlobal

Phil Taylor ArisGlobal, Boehringer Ingelheim, digital, digital health, pharmacovigilance, safety 0 Comment

German drugmaker Boehringer Ingelheim has sold an artificial intelligence-powered software platform it developed to monitor drug safety data

Boehringer sells drug safety software to ArisGlobal

https://pharmaphorum.com/news/boehringer-sells-drug-safety-software-to-arisglobal/

News/ News/ R&D

AZ bites back at rivals with new Farxiga data in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiovascular disease, Eli Lilly, Farxiga, heart failure 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it

AZ bites back at rivals with new Farxiga data in heart failure

https://pharmaphorum.com/news/az-bites-back-at-rivals-with-new-farxiga-data-in-heart-failure/

News/ News/ Sales and Marketing

Boehringer plans €25bn R&D spend, fuelled by Jardiance

Phil Taylor Boehringer Ingelheim, Financial, immunology, Jardiance, Oncology, R&D 0 Comment

Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over

Boehringer plans €25bn R&D spend, fuelled by Jardiance

https://pharmaphorum.com/news/boehringer-plans-e25bn-rd-spend-fuelled-by-jardiance/

Market Access/ News/ News

Jardiance pulls ahead of Forxiga with heart failure approval in EU

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance has become the first drug in the class to be

Jardiance pulls ahead of Forxiga with heart failure approval in EU

https://pharmaphorum.com/news/jardiance-pulls-ahead-of-forxiga-in-european-heart-failure-market/

News/ News/ R&D

Stage set for Jardiance to become universal heart failure drug

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting

Stage set for Jardiance to become universal heart failure drug

https://pharmaphorum.com/news/stage-set-for-jardiance-to-become-universal-heart-failure-drug/

Market Access/ News/ News

FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure

Eloise McLennan Boehringer Ingelheim, Eli Lilly, FDA approval, heart disease, pharma 0 Comment

Eli Lilly and Boehringer Ingelheim’s blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food

FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure

https://pharmaphorum.com/news/fda-approves-jardiance-empagliflozin-for-wider-range-of-patients-with-heart-failure/

News/ News/ R&D

PureTech challenges Roche’s Esbriet in head-to-head IPF trial

Phil Taylor Boehringer Ingelheim, Esbriet, fibrosis, idiopathic pulmonary fibrosis, Ofev, PureTech Health, Roche, safety 0 Comment

Roche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market,

PureTech challenges Roche’s Esbriet in head-to-head IPF trial

https://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/

News/ News/ R&D

Boehringer’s spesolimab data raises hope for serious skin disease

Phil Taylor Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab 0 Comment

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim’s spesolimab has shown encouraging efficacy in

Boehringer’s spesolimab data raises hope for serious skin disease

https://pharmaphorum.com/news/boehringers-spesolimab-data-raises-hope-for-serious-skin-disease/

Trending

Boehringer Ingelheim

Login